Dexmedetomidine Hydrochloride is a drug owned by Hq Specialty Pharma Corp. It is protected by 2 US drug patents filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 20, 2036. Details of Dexmedetomidine Hydrochloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9717796 | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(11 years from now) | Active |
| US9649296 | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dexmedetomidine Hydrochloride's patents.
Latest Legal Activities on Dexmedetomidine Hydrochloride's Patents
Given below is the list of recent legal activities going on the following patents of Dexmedetomidine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 20 Jan, 2021 | US9717796 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 09 Oct, 2020 | US9717796 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 24 Sep, 2020 | US9649296 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Aug, 2017 | US9717796 |
| Recordation of Patent Grant Mailed Critical | 01 Aug, 2017 | US9717796 |
| Application ready for PDX access by participating foreign offices Critical | 13 Jul, 2017 | US9717796 |
| Email Notification Critical | 13 Jul, 2017 | US9717796 |
| Issue Notification Mailed Critical | 12 Jul, 2017 | US9717796 |
| Dispatch to FDC | 28 Jun, 2017 | US9717796 |
| Application Is Considered Ready for Issue Critical | 27 Jun, 2017 | US9717796 |
US patents provide insights into the exclusivity only within the United States, but Dexmedetomidine Hydrochloride is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dexmedetomidine Hydrochloride's family patents as well as insights into ongoing legal events on those patents.
Dexmedetomidine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dexmedetomidine Hydrochloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 20, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dexmedetomidine Hydrochloride Generic API suppliers:
Dexmedetomidine Hydrochloride is the generic name for the brand Dexmedetomidine Hydrochloride. 25 different companies have already filed for the generic of Dexmedetomidine Hydrochloride, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Dexmedetomidine Hydrochloride's generic
Alternative Brands for Dexmedetomidine Hydrochloride
There are several other brand drugs using the same active ingredient (Dexmedetomidine Hydrochloride) as Dexmedetomidine Hydrochloride. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Dexmedetomidine Hydrochloride, Dexmedetomidine Hydrochloride's active ingredient. Check the complete list of approved generic manufacturers for Dexmedetomidine Hydrochloride
About Dexmedetomidine Hydrochloride
Dexmedetomidine Hydrochloride is a drug owned by Hq Specialty Pharma Corp. Dexmedetomidine Hydrochloride uses Dexmedetomidine Hydrochloride as an active ingredient. Dexmedetomidine Hydrochloride was launched by Hq Spclt Pharma in 2015.
Approval Date:
Dexmedetomidine Hydrochloride was approved by FDA for market use on 21 October, 2015.
Active Ingredient:
Dexmedetomidine Hydrochloride uses Dexmedetomidine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Dexmedetomidine Hydrochloride ingredient
Dosage:
Dexmedetomidine Hydrochloride is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |